SEARCH

SEARCH BY CITATION

References

  • 1
    Mowat AM, Faria AM, Weiner HL Oral tolerance: physiological basis and clinical applications. In: MesteckyJ, LammME, StroberW, BienenstockJ, McGheeJR, MayerL, eds. Mucosal Immunology, Vol 1, 3rd edn. Amsterdam: Elsevier, 2005:487537.
  • 2
    Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S4553.
  • 3
    Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med 2009;103:80012.
  • 4
    Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994;91:107959.
  • 5
    Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996;93:7196201.
  • 6
    Bergerot I, Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:46104.
  • 7
    Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum 1999;42:162834.
  • 8
    Sun J-B, Xiao B-G, Lindblad M et al. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing TGF-β1 secreting cells and suppressing chemokine expression. Int Immunol 2000;12:144957.
  • 9
    Phipps PA, Stanford MR, Sun JB et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 2003;33:2432.
  • 10
    Czerkinsky C, Anjuere F, McGhee JR et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999;170:197222.
  • 11
    Rask C, Holmgren J, Fredriksson M, Nordstrom I, Sun JB, Czerkinsky C. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin Exp Allergy 2000;30:102432.
  • 12
    McSorley SJ, Rask C, Plchot R, Julia V, Czerkinsky C, Glaichenhatis N. Selective tolerization of Thl-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur J Immimol 1998;28:42432.
  • 13
    Sun JB, Mielcarek N, Lakew M et al. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J Immunol 1999;163:104552.
  • 14
    Stanford M, Whittall T, Bergmeier LA et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet’s disease. Clin Exp Immunol 2004;137:2018.
  • 15
    Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998;16:9348.
  • 16
    Carter JE, Yu J, Choi NW et al. Bacterial and plant enterotoxin B subunit-autoantigen fusion proteins suppress diabetes insulitis. Mol Biotechnol 2006;32:115.
  • 17
    Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H. Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts – oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J 2007;5:495510.
  • 18
    Bublin M, Hoflehner E, Wagner B et al. Use of a cholera toxin B subunt/allergen-fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune response. Vaccine 2007;25:8395404.
  • 19
    Yuki Y, Byun Y, Fujita M et al. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol Bioeng 2001;74:629.
  • 20
    Scerbo MJ, Rupil LL, Bibolini MJ, Roth GA, Monferran CG. Protective effect of a synapsin peptide genetically fused to the B subunit of Escherichia coli heat-labile enterotoxin in rat autoimmune encephalomyelitis. J Neurosci Res 2009;87:227381.
  • 21
    Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 1999;48:21506.
  • 22
    Aspord C, Czerkinsky C, Durand A, Stefanutti A, Thivolet C. α4 Integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin. J Autoimmun 2002;19:22332.
  • 23
    Aspord C, Thivolet C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 2002;130:20411.
  • 24
    Petersen JS, Bregenholt S, Apostolopolous V et al. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin Exp Immunol 2003;134:3845.
  • 25
    Gong Z, Jin Y, Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine 2007;25:144451.
  • 26
    Gong Z, Long X, Pan L et al. Cloning, expression, purification and characterization of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion protein in Escherichia coli. Protein Expr Purif 2009;66:1917.
  • 27
    Yuki Y, Hara-Yakoyama C, Guadiz AA, Udaka S, Kiyono H, Chatterjee S. Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes. Biotechnol Bioeng 2005;92:8039.
  • 28
    Denes B, Krausova V, Fodor N, Takatsy Z, Fodor I, Langridge WH. Protection of NOD mice from type 1 diabetes after oral inoculation with vaccinia viruses expressing adjuvanted islet autoantigens. J Immunother 2005;28:43848.
  • 29
    Kim N, Cheng KC, Kwon SS, Mora R, Barbieri M, Yoo TJ. Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease. Ann Otol Rhinol Laryngol 2001;110:64654.
  • 30
    Tamura S, Hatori E, Tsuruhara T, Aizawa C, Kuraia T. Suppression of delayed-type hyper sensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enicroioxin B subunit-conjugated ovaibumin. Vaccine 1997;15:2259.
  • 31
    Saito K, Shoji J, Inada N, Iwasaki Y, Sawa M. Immunosuppressive effect of cholera toxin B on allergic conjunctivitis model in guinea pig. Jpn J Ophthalmol 2001;45:3328.
  • 32
    Anjuere F, George-Chandy A, Audant F, Rousseau D, Holmgren J, Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 2003;170:158692.
  • 33
    Cuburu N, Kweon MN, Song JH, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007;25:8598610.
  • 34
    Smits HH, Gloudemans AK, Van Nimwegen M et al. Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. Mucosal Immunol 2009;2:3319.
  • 35
    Wiedermann U, Jahn-Schmid B, Lindblad M et al. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Int Immunol 1999;11:171724.
  • 36
    Takagi H, Hiroi T, Yang L, Takamura K et al. Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed. Vaccine 2008;26:602730.
  • 37
    Czerkinsky C, Holmgren J. The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccines. Immunologist 1995;3:97103.
  • 38
    Sun J-B, Raghavan S, Lundin S, Sjöling A, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+CD4+ and Foxp3CD25-CD4+ regulatory T cells. J Immunol 2006;177:763444.
  • 39
    Sun JB, Czerkinsky C, Holmgren J. Sublingual ‘oral tolerance’ induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand J Immunol 2007;66:27886.
  • 40
    Sun J-B, Flach C-F, Czerkinsky C, Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J Immunol 2008;181:827887.
  • 41
    Luross JA, Heaton T, Hirst TR et al. Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum 2002;46:167182.
  • 42
    Bettelli E, Carrier Y, Gao W, Day MJ, Williams NA. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:2368.
  • 43
    Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation. J Exp Med 2007;204:151924.
  • 44
    So JS, Lee CG, Kwon HK et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 2008;46:17280.
  • 45
    Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13:14357.
  • 46
    Strobel S, Mowat AM. Oral tolerance and allergic responses to food proteins. Curr Opin Allergy Clin Immunol 2006;6:20713.
  • 47
    Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001;167:424553.
  • 48
    Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:53162.
  • 49
    Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004;172:521321.
  • 50
    Vieira PL, Christensen JR, Minaee S et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4(+)CD25(+) regulatory T cells. J Immunol 2004;172:598693.
  • 51
    George-Chandy A, Hultkrantz S, Raghavan S et al. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25-T cells. Immunology 2006;118:31120.
  • 52
    Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:187586.
  • 53
    Ma D, Li X-Y, Mellon J, Niederkorn JY. Immunological phenotype of hosts orally tolerized with corneal alloantigens. Invest Ophthalmol Vis Sci 1998;39:74453.
  • 54
    Sun JB, Cuburu N, Blomquist M, Li BL, Czerkinsky C, Holmgren J. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 2006;64:2519.
  • 55
    Leal-Berumen I, Snider DP, Barajas-Lopez C, Marshall JS. Cholera toxin increases IL-6 synthesis and decreases TNF-alpha production by rat peritoneal mast cells. J Immunol 1996;156:31621.
  • 56
    Pandiyan P, Zheng L, Ishihara S et al. CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation mediated apoptosis of effector CD4(+) T cells. Nat Immunol 2007;8:135362.
  • 57
    Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009;182:403645.
  • 58
    Gonnella PA, Waldner HP, Weiner HL. B cell-deficient (mu MT) mice have alterations in the cytokine microenvironment of the gut-associated lymphoid tissue (GALT) and a defect in the low dose mechanism of oral tolerance. J Immunol 2001;166:445664.
  • 59
    Andersson J, Tran DQ, Pesu M et al. CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-{beta}-dependent manner. J Exp Med 2008;205:197581.
  • 60
    Gandhi R, Anderson DE, Weiner HL. Cutting edge: immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner. J Immunol 2007;178:401721.
  • 61
    Ali NA, Gaughan AA, Orosz CG et al. Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1. PLoS ONE 2008; 3:e1914.
  • 62
    Chen ML, Yan BS, Bando Y et al. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGF{beta}-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 2008;180:732737.
  • 63
    Korn T, Reddy J, Gao W et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007;13:42331.
  • 64
    Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev 2005;206:13248.
  • 65
    Coombes JL, Siddiqui KR, Arancibia-Carcamo CV et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-{beta}- and retinoic acid-dependent mechanism. J Exp Med 2007;204:175764.
  • 66
    Von Boehmer H. Oral tolerance: is it all retinoic acid? J Exp Med 2007;204:17379.
  • 67
    D’Ambrosio A, Colucci M, Pugliese O, Quintieri F, Boirivant M. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J Leukoc Biol 2008;84:6618.
  • 68
    George Chandy A, Eriksson E, Lebens M, Nordström I, Schön E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen presenting cells. Infect Immun 2001;69:571625.
  • 69
    Pasare C, Medzhitov R. Cell-mediated suppression by dendritic cells Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:10336.
  • 70
    Contractor N, Louten J, Kim L, Biron CA, Kelsall BL. Cutting Edge: Peyer’s Patch Plasmacytoid Dendritic Cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J Immunol 2007;179:26904.
  • 71
    Anjuere F, Lebenz M, Rousseau D et al. . In vivo CTB-induced oral tolerance towards antigen specific CD4+ T cells is mediated by a discrete subset of mesenteric dendritic cells. Abstract 52734 at the 12th International congress of mucosal immunology, Boston, 2005.
  • 72
    Li BL, Sun JB, Holmgren J. Adoptive transfer of mucosal T cells or dendritic cells from animals fed with cholera toxin B subunit alloantigen conjugate induces allogeneic T cell tolerance. Adv Exp Med Biol 2001;495:2715.
  • 73
    Liang B, Mamula MJ. Molecular mimicry and the role of B lymphocytes in the processing of autoantigens. Cell Mol Life Sci 2000;57:5618.
  • 74
    Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor αmutant mice. J Exp Med 1997;186:174956.
  • 75
    Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489501.
  • 76
    Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001;167:10819.
  • 77
    Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996;184:22718.
  • 78
    Zouali M. B lymphocytes – chief players and therapeutic targets in autoimmune diseases. Front Biosci 2008;13:485261.
  • 79
    Hoehlig K, Lampropoulou V, Roch T et al. Immune regulation by B cells and antibodies a view towards the clinic. Adv Immunol 2008;98:138.
  • 80
    Chen X, Jensen PE. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 2007;179:204650.
  • 81
    Shah S, Qiao L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol 2008;38:248898.
  • 82
    Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:94450.
  • 83
    Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:70510.